Summer Sale
50% off Premium Yearly
Apotex Health (APTX.TO)
Financials 
Technical Analysis 
Aug 27, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Apotex Health (APTX-T) is gaining attention as a significant player in the Canadian pharmaceutical landscape, specializing in conventional, specialty, and biosimilar generic drugs. Despite facing substantial competition from established companies such as CAH and MCK, the firm is witnessing remarkable growth, particularly as numerous branded drugs are set to go off patent in the coming years. Analysts highlight the company's cleaner balance sheet post-IPO and note the potential for a first-mover advantage in the burgeoning GLP-1 market, which could enable APTX to capture a significant market share. However, some experts express caution, preferring to observe more trading history before making an investment, while others remain wary of the company's high debt levels stemming from a leveraged buyout. Overall, APTX shows promise as it continues to expand its reach in the U.S. and abroad, pushing beyond generics into biosimilars with potentially higher margins.
Largest manufacturer of conventional, specialty, and biosimilar generic drugs in Canada. Cleaner balance sheet since the IPO. Big near-term catalyst is GLP-1 market; first-mover advantage could lead it to capture 20% or more of that market. Lots of branded pharmaceuticals going off patent in Canada in next 5 years.
Good-sized position in US, growing organically there as well. No dividend.
Brian MaddenLooks impressive, but he likes a bit more trading history before jumping in. (Interestingly, the IPO came out just before SpaceX, and APTX has outperformed it.) Seeing amazing growth, as well as projected growth. Moving beyond generics to biosimilars (take long to be approved, not as much risk, margins tend to be higher). Expanding to US and beyond.
- «
- ‹
- 1
- ›
- »
Popular Articles
Apotex Health (APTX.TO) Frequently Asked Questions
What is Apotex Health stock symbol?
Apotex Health is a OTC stock, trading under the symbol APTX.TO (previously APTX-T on Stockchase) on the undefined (undefined). It is usually referred to as or APTX.TO
Is Apotex Health a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on APTX.TO (previously APTX-T on Stockchase). 1 analyst recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is DON'T BUY. Read the latest stock experts' ratings for Apotex Health.
Is Apotex Health a good investment or a top pick?
Apotex Health was recommended as a Top Pick by Barry Schwartz on 2026-08-19. Read the latest stock experts ratings for Apotex Health.
Why is Apotex Health stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Apotex Health.
Is Apotex Health worth watching?
Apotex Health is followed by 13 investors on Stockchase and is a trending stock that is worth watching.
Pretty good business. Lots of competition from the likes of CAH and MCK. The way we deliver drugs is changing quickly. Lots of debt due to the leveraged buyout. He's watching, but not interested at the moment. Probably won't do much for a long time.